Pamiparib

Pamiparib (CAS No.: 1446261-44-4) is a potent and selective poly(ADP-ribose) polymerase (PARP) inhibitor, primarily targeting PARP1 and PARP2 enzymes, with IC50 values of 0.9 nM and 0.5 nM, respectively. By inhibiting PARP enzymatic activity, it disrupts DNA damage repair processes, leading to tumor cell death, and shows significant anti-proliferative activity particularly in tumor cells carrying BRCA1/2 mutations or homologous recombination repair deficiency (HRD). In vitro studies show that Pamiparib can effectively inhibit tumor cell proliferation at nanomolar to low micromolar levels. It is commonly used in cell and animal models to evaluate anti-tumor activity, and the dose or concentration used in experiments typically depends on the experimental design and research objectives.